ライフサイエンスコーパス: proptosis

1 east severe disease state (no diplopia/small proptosis).

2 ssen the risk of postoperative recurrence of proptosis.

3 o our attention was the sudden onset of left proptosis.

4 who presented with facial pain and right eye proptosis.

5 atment to improve visual acuity greater than proptosis.

6 evealed a lacrimal fossa pseudotumor causing proptosis.

7 OI in patients with a new-onset complaint of proptosis.

8 4-0.36), followed by constant diplopia/small proptosis (0.34; 95% CI, 0.29-0.40), intermittent or inc

9 ), intermittent or inconstant diplopia/large proptosis (0.43; 95% CI, 0.36-0.49), no diplopia/large p

10 (0.43; 95% CI, 0.36-0.49), no diplopia/large proptosis (0.46; 95% CI, 0.40-0.52), and intermittent or

11 nd intermittent or inconstant diplopia/small proptosis (0.52; 95% CI, 0.45-0.58).

12 provement of BCVA (0.53 +/- 0.47 logMAR) and proptosis (0.59 +/- 0.66 mm) (both p < 0.001).

13 Eyelid edema (13/32, 41%) and proptosis (12/32, 38%) were the most frequent presentati

14 was an improvement of BCVA (0.2 logMAR) and proptosis (2 mm) in 76.5, and 5.9% respectively.

15 1 (59% [24] vs. 21% [9]), the mean change in proptosis (-2.82 mm vs. -0.54 mm), diplopia response (68

16 nders or those who flared ( 2-mm increase in proptosis, 2-point increase in clinical activity score [

17 ebo achieved a significant mean reduction of proptosis (-3.0 mm vs. -0.3 mm, phase 2 study; -3.32 mm

18 y (EOM) restriction (78.6% vs 38.8% P<0.01), proptosis (64.3% vs 21.2%, P<0.01), elevated intraocular

19 AS points and a reduction of 2 mm or more in proptosis (69% vs. 20%; P < 0.001; phase 2 study) and pr

20 as defined by a reduction of 2 mm or more in proptosis (83% vs. 10%; P < 0.001; phase 3 study).

21 or minimal inflammation), the mean change in proptosis across trial visits (from baseline through wee

22 ociated with the postoperative recurrence of proptosis after orbital decompression.

23 mprovement in proptosis in the eye with more proptosis after teprotumumab was 1.57mm (range, -3 to 4

24 patients complained of new-onset progressive proptosis although their thyroid disease was controlled

25 The proptosis and CAS regression occurs in the setting of di

26 port highlights a case in which sudden axial proptosis and corneal perforation revealed underlying GP

27 disease presenting with apparent unilateral proptosis and determine the occurrence of exophthalmos i

28 nset of ocular pain, upper eye lid swelling, proptosis and diplopia after a commercial flight.

29 disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of l

30 Gradually progressive proptosis and eyelid swelling were the most common prese

31 Decrease in proptosis and improvement in extraocular movements were

32 , is associated with greater improvements in proptosis and may be twice as likely to have a 1 grade o

33 Complete resolution of proptosis and restoration of ocular motility were seen i

34 (TED) is a serious condition that can cause proptosis and strabismus and, in rare cases, lead to bli

35 was more effective than placebo in reducing proptosis and the Clinical Activity Score.

36 On ocular examination, there was proptosis and total ophthalmoplegia with loss of corneal

37 In patients presenting with painful proptosis and vision loss, a diagnosis of BL should be c

38 and clinical activity score >=4, +/-diplopia/proptosis) and refined using interviews with US patients

39 ived it) was 2 +/- 2 for CAS, 2 +/- 4 mm for proptosis, and 1 +/- 1 for diplopia score.

40 e right eye pain, pain with ocular movement, proptosis, and conjunctival injection.

41 resent with abrupt or insidious visual loss, proptosis, and disturbance of ocular motility.

42 ment, minimal diplopia, the usual absence of proptosis, and general preservation of visual acuity.

43 dered especially in patients with refractory proptosis, and lead to its further evaluation and prompt

44 ariable and include eyelid swelling, ptosis, proptosis, and loss of vision.

45 atients in Group 1 had mild residual ptosis, proptosis, and movement restriction at 12 weeks, none of

46 pital stay, and sequelae of disease (ptosis, proptosis, and movement restriction) were evaluated and

47 milar findings: periorbital edema, erythema, proptosis, and pain.

48 Further, the clinical activity score (CAS), proptosis, and the Gorman diplopia score were reviewed a

49 : 5.10, 95%CI: 1.061-24.501, p = 0.042); and proptosis at baseline (OR: 9.31, 95%CI: 1.872-46.280, p

50 1-day old infant who presented with dramatic proptosis at birth due to a true congenital orbital tera

51 lmopathy) and a reduction of 2 mm or more in proptosis at week 24.

52 nied by eye displacement, including rhythmic proptosis, attributable to masseter contractions.

53 the recurrence of strabismus, diplopia, and proptosis, but did not correct deficits in the best corr

54 Changes in proptosis by millimeter and diplopia response (percentag

55 In these responders, proptosis, CAS of 0 or 1, and diplopia responses were ma

56 Secondary outcomes included proptosis, CAS, subjective diplopia, and quality-of-life

57 atching-adjusted indirect comparison (11 for proptosis change [n = 419], 4 for diplopia response [n =

58 g mass leading to a massive unilateral axial proptosis, chemosis, exposure keratopathy, markedly dist

59 resulted in better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and qualit

60 The left eye exhibited axial proptosis, conjunctival congestion, chemosis, and a smal

61 Treatment with IVMP resulted in a proptosis difference of -0.16 mm (95% CI, -1.55 to 1.22

62 tial disutility, with increasing severity of proptosis/diplopia more likely to have detrimental assoc

63 sed that rectus muscle paralysis would cause proptosis due to the reduction in active posterior tensi

64 age, gender, clinical activity score (CAS), proptosis, duration of disease, and margin to reflex dis

65 patients, 11 (5.1%) developed recurrence of proptosis during the follow-up period (range, 3-30; mean

66 eriorbital (e.g., superior sulcus hollowing, proptosis, enophthalmos, hypoglobus, and hyperglobus).

67 for surgery include age older than 9 years, proptosis, EOM restriction, and elevated IOP.

68 ted between the ages of 29 and 76 years with proptosis, eyelid swelling or a mass (10/14 cases), and

69 ders or those who flared (>=2-mm increase in proptosis, >=2-point increase in clinical activity score

70 frequent fractures, craniosynostosis, ocular proptosis, hydrocephalus, and distinctive facial feature

71 Proptosis improved by 2 mm or more in 77% of patients (1

72 At 12 months, muscle volume and proptosis improved slightly more in the orbit that was t

73 e in 77% of patients (101/131), with average proptosis improvement of 3.0 +/- 2.1 mm and average CAS

74 tative orbital decompression for disfiguring proptosis in an inactive state with a low clinical activ

75 ted with a five-month history of progressive proptosis in his left eye, associated with a gradual dec

76 we were able to quantify the degree of axial proptosis in patients with GO.

77 The average long-term improvement in proptosis in the eye with more proptosis after teprotumu

78 l fat expansion and consequently more severe proptosis in thyroid eye disease.

79 was reactivation, defined as a regression in proptosis (increase of >=2 mm in either eye and to withi

80 evated intraocular pressure occurring during proptosis induced choroidal ischemia and that acoustic r

81 arget organ in relapsing polychondritis, and proptosis is a well-recognized manifestation of eye invo

82 equent event, while subsequent contralateral proptosis occurs less commonly.

83 ome was a proptosis response (a reduction in proptosis of >=2 mm) at week 24.

84 Clinical Activity Score plus a reduction in proptosis of >=2 mm), a Clinical Activity Score of 0 or

85 ternal examination revealed 3 cm of relative proptosis of the left eye and a palpable mass in the lef

86 e presented with rapidly progressive painful proptosis of the right eye and poor visual acuity.

87 mphoma (BL) with rapidly progressive painful proptosis of the right eye is rarely encountered.

88 between obesity and orbital fat expansion in proptosis of thyroid eye disease.

89 immune disorder characterized by progressive proptosis or diplopia.

90 Vision was unaffected and there was no proptosis or globe displacement.

91 gns or symptoms, others lead to vision loss, proptosis, or precocious puberty.

92 left eye associated with slowly progressive proptosis over the previous 6 months.

93 ses, at baseline, no difference was found in proptosis (P = 0.07), diplopia score (P = 0.4), or durat

94 associated with development of contralateral proptosis (p< .05).

95 ols (P<0.0001) and inversely correlated with proptosis (P<0.0001) and lid fissure (P<0.045).

96 ients with GO between the CA-to-OA ratio and proptosis (P<0.001), lid fissure (P = 0.004), and intrao

97 His symptoms included right eye proptosis, periocular edema and redness.

98 aluation was 24 months, with nasal symptoms, proptosis, periorbital swelling, and pain being the most

99 dation and death, coronal synostosis, ocular proptosis, precocious sternal fusion, and abnormalities

100 teration in physical appearance secondary to proptosis, ptosis, and facial disfigurement, leading to

101 ed with a 20-day history of painful left eye proptosis, purulent discharge, photophobia, and progress

102 Proptosis ranged from 4 mm to 9 mm (median, 5.5 mm; mean

103 ction after surgery at follow-up and orbital proptosis recovered in all patients with these symptoms.

104 TRAb and TSI are valuable markers to predict proptosis recurrence after orbital decompression.

105 sociation between preoperative variables and proptosis recurrence was analyzed using multivariable lo

106 -treated in OPTIC-X, 2 responded, 1 showed a proptosis reduction of 1.5 mm from OPTIC baseline, and 2

107 ents (62.5%) responded when re-treated (mean proptosis reduction, 1.9 +/- 1.2 mm from OPTIC-X baselin

108 ents (62.5%) responded when re-treated (mean proptosis reduction, 1.9 1.2 mm from OPTIC-X baseline an

109 his effect is independent from the amount of proptosis reduction.

110 n MPLDs did not correlate with the extent of proptosis reduction.

111 re were 8 reactivations (47%) and 2 isolated proptosis regressions (12%); Overall, 7 of 21 patients (

112 ngle closure glaucoma presented with 4 mm of proptosis, resistance to retropulsion, tortuous corkscre

113 (69% vs. 20%; P < 0.001; phase 2 study) and proptosis responder rate as defined by a reduction of 2

114 lacebo-treated OPTIC patients (89.2%) became proptosis responders (mean +/- standard deviation, -3.5

115 lacebo-treated OPTIC patients (89.2%) became proptosis responders (mean standard deviation, -3.5 1.7

116 e re-treated group, 82% showed a significant proptosis response (>= 2-mm reduction from baseline) aft

117 The primary outcome was a proptosis response (a reduction in proptosis of >=2 mm)

118 t re-treated showed a clinically significant proptosis response (P = 0.16).

119 t week 24, the percentage of patients with a proptosis response was higher with teprotumumab than wit

120 AE severity, AE reversibility, AE duration, proptosis response, clinical activity score (CAS) reduct

121 omise, including teprotumumab, which reduces proptosis, rituximab (anti-CD20), which reduces inflamma

122 MI was an independent factor predicting both proptosis severity (P < 0.001) and removed orbital fat v

123 res included the association of obesity with proptosis severity, removed fat volume, and thyroid stat

124 3.76 mm) exhibited significantly more severe proptosis than participants without overweight (18.05 +/

125 , measured as continuous variables, included proptosis, the Clinical Activity Score, and results on t

126 The proptosis treatment difference between IVMP and teprotum

127 ions such as hypotony, diplopia, strabismus, proptosis, tube erosion, failure, corneal decompensation

128 phic lesions that resemble scars, thin hair, proptosis, underdeveloped cheekbones, and marked acro-os

129 clinically relevant, change from baseline in proptosis vs placebo, with modest changes in diplopia.

130 0.63 logMAR (p < 0.001) and the decrease in proptosis was 1.8 +/- 1.36 mm (p < 0.001).

131 Mean proptosis was 6.7 +/- 4.6 mm.

132 The mass regressed and the amount of proptosis was decreased in both patients.

133 r a traumatic fall, he was hospitalized, and proptosis was identified at physical examination.

134 Visual loss was present in 3 patients and proptosis was present in 19 patients.

135 The reduction in proptosis was similar among those with and without oscil

136 t of best corrected visual acuity (BCVA) and proptosis were compiled.

137 ination, conjunctival edema and redness with proptosis were noted.

138 Other common findings include diplopia, proptosis (which is generally minimal), conjunctival inj

139 Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Teprotumumab Infusions in a Randomized, P

140 e Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab Infusions in an Open-Label C

141 evere disease state (constant diplopia/large proptosis) with 0.30 (95% CI, 0.24-0.36), followed by co